Host Defense Peptides and Cancer; Perspectives on Research Design and Outcomes
1Institute of Medical Microbiology, Semmelweis University, Budapest 1088, Hungary and OLPE, LLC, Audubon, PA 19403. United States.
Abstract:
Antimicrobial peptides (AMP) inhibit the proliferation of bacteria and frequently protect experimental animals from bacterial challenge. If the mode of action is membrane disintegration, one would expect that AMP can also kill cancer cells whose membrane structure lies between those of normal and bacterial cells. However, an ever-increasing number of reports suggest that AMP, with their newer name, host-defense peptides (HDP), do not directly kill bacteria under in vitro conditions when small molecule antibacterials are bactericidal. The micromolar activity may be suitable for biochemical studies but does not warrant oncology drug development. Nevertheless, as HDP are also documented to act on intracellular targets, the alternative modes of action revive the belief that antiproliferative efficacy can be obtained, indeed supported by a few successful animal efficacy studies. In addition, the passive transport properties of AMP/HDP can be utilized in the intracellular delivery of unrelated cancer drugs. Unfortunately the inherent pro-inflammatory activities of many native and designer HDP lead to oncogenic rather than anti-cancer activities in vitro and in vivo. A critical evaluation of the role of HDP in tumor development with pharmaceutically relevant animal efficacy and toxicity studies are needed before human clinical trials can be designed and initiated.
Insights
Antimicrobial peptides (AMP), now known as host-defense peptides (HDP), show limited direct bacterial killing and anticancer potential. Their pro-inflammatory effects may even promote oncogenesis, requiring further study before clinical use.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Antimicrobial peptides (AMPs) are known for antibacterial properties and potential in protecting against bacterial infections.
- The membrane structure of cancer cells suggests AMPs might also target them, but recent findings challenge this direct cytotoxic effect.
- Host-defense peptides (HDPs), the newer term for AMPs, exhibit varying efficacy, with some showing only micromolar activity unsuitable for direct oncology drug development.
Purpose of the Study:
- To critically evaluate the role of host-defense peptides (HDPs) in cancer therapy.
- To assess the potential of HDPs as direct anticancer agents versus their utility in drug delivery.
- To investigate the dual nature of HDPs, considering both antiproliferative effects and pro-inflammatory activities.
Main Methods:
- Review of existing literature on AMP/HDP activity against bacteria and cancer cells.
- Analysis of studies investigating intracellular targets and drug delivery capabilities of HDPs.
- Evaluation of in vitro and in vivo data regarding HDPs' inflammatory and oncogenic potential.
Main Results:
- HDPs demonstrate limited direct bacterial killing compared to traditional antibacterials.
- While some HDPs show antiproliferative effects via intracellular targets and potential in drug delivery, direct cancer cell killing is not consistently observed.
- Inherent pro-inflammatory activities of many HDPs can lead to oncogenic effects rather than anticancer benefits.
Conclusions:
- HDPs' direct anticancer efficacy is questionable due to limited direct bacterial killing and potential oncogenic side effects.
- The utility of HDPs in cancer may lie in their intracellular targeting or as drug delivery vehicles rather than direct cytotoxic agents.
- Further research, including pharmaceutically relevant animal efficacy and toxicity studies, is crucial before considering HDPs for human clinical trials in oncology.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...